Navigation Links
Harbinger Research Initiates Coverage on China Baicaotang Medicine, Ltd.
Date:5/11/2010

LIUZHOU CITY, China, May 11 /PRNewswire-Asia-FirstCall/ -- China Baicaotang Medicine Ltd. (OTC Bulletin Board: CNBI) ("CBT," or the "Company"), a provincial leader in pharmaceutical distribution and retailing in the Guangxi Province of China announced today that Harbinger Research, LLC, an independent equity research firm, will provide research coverage on the Company.

Mr. Tang Hui Tian, Chairman and CEO of CBT, stated that "Our Company is in the midst of growth and expansion in Guangxi province, and given our status as a U.S.-traded Company and plans to up-list to a national exchange in the near future, we feel Harbinger Research's coverage of CBT comes at an excellent time for CBT and its investors. We believe our company and industry will continue to demonstrate robust growth for years to come, as per-capita disposable income and government-driven pharmaceutical spending in China continue to grow."

Brian R. Connell, CFA, a Harbinger Research Senior Analyst, stated that, "We are excited to initiate coverage on China Baicaotang, which we believe is significantly undervalued on both a relative and absolute basis. We expect the pharmaceutical industry to remain strong in China for the foreseeable future, clearly benefiting all provincial industry leaders, including China Baicaotang."

To view Harbinger Research's coverage initiation on China Baicaotang Medicine, Ltd., rated by Brian R. Connell, CFA, please click on the following link: http://www.harbingerresearch.com/link/13/253/CNBI

About China Baicaotang Medicine, Ltd.

China Baicaotang is a vertically-integrated pharmaceutical company that operates in the Guangxi Province of China. The Company's three operating subsidiaries include a drug and herbal remedy manufacturing company, a pharmaceutical distributor that carries over 8,000 products, and a retail drugstore chain with 66 stores throughout the Guangxi province. The company is an emerging leader in this region of the PRC, and its shares currently traded on the OTC:BB under the symbol CNBI. Learn more http://www.china-bct.com .

About Harbinger Research, LLC

Harbinger Research is an independent equity research that employs a research team consisting entirely of CFA charter holders and follows a number of companies across a wide variety of industries. Harbinger Research makes all of its reports available through its website at http://www.harbingerresearch.com , and also distributes content through a variety of partners, including InvestorsInsight Publishing, and through most major financial portals.

Safe Harbor Statement

Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.

    For more information, please contact:

    China Baicaotang Medicine, Ltd. Investor Contact:
     Shelly Zhang
     Chief Financial Officer
     China Baicaotang Medicine Limited
     Email: z_shelly@hotmail.com
     Tel:   +86-772-363-8318
     Web:   http://www.china-bct.com


'/>"/>
SOURCE China Baicaotang Medicine Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Fate Therapeutics Appoints Tom Novak, Ph.D., as Vice President of Research and Drug Discovery
2. Orexigen(R) Therapeutics to Speak at Ninth Annual JMP Securities Research Conference
3. Silence Therapeutics Appoints New Vice President of Research
4. UCLA researchers use new microscope to see atoms for first time
5. TB Alliance and AstraZeneca Form Research Collaboration to Fight Tuberculosis
6. Knome Announces KnomeDISCOVERY Research Awards Program
7. The New York Stem Cell Foundation and The Johns Hopkins University School of Medicine to Collaborate on Stem Cell Research
8. Web-Based Management Suite Supports Complex Research Consortia
9. German MedSys Project Adopts Genedata Phylosopher for Research Informatics
10. New technique reinforces immune cells that seek and destroy cancer, says Stanford researcher
11. Materials research advances reliability of faster smart sensors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... ... July 24, 2017 , ... Charm Sciences, Inc. is pleased to announce ... Conference on Interstate Milk Shipments (NCIMS) Laboratory Committee and Appendix N Committee as a ... 1, 2017. , The NCIMS voted at its annual meeting in April, 2015 to ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... of leading radiology and imaging centers around the U.S. that offer MR Elastography ... accurate alternative to needle biopsy for staging liver fibrosis assessment. , “MRE:connect ...
(Date:7/20/2017)... DENVER and PLYMOUTH, Minn., July 20, 2017 ... LLC , a personalized genetic evaluations company, today ... under their partnership investigating a genetic mutation implicated ... to extend the partnership for a second case ... Last year, the KCNQ2 Cure Alliance and Pairnomix ...
(Date:7/18/2017)... , ... July 18, 2017 , ... ... announced that Merck, a leading science and technology company, has implemented Genedata ... for the therapeutic areas of Oncology, Immunology, and Neurodegenerative Diseases. , The need ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:3/30/2017)... March 30, 2017 The research team of ... three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint minutiae ... realm of speed and accuracy for use in identification, crime investigation, ... cost. ... A research ...
(Date:3/24/2017)... , March 24, 2017 The Controller General ... Controller Mr. Abdulla Algeen have received the prestigious international IAIR ... Continue Reading ... ... picture) and Deputy Controller Abdulla Algeen (small picture on the right) have ...
Breaking Biology News(10 mins):